SCHEMBL23456293

SCHEMBL23456293

COC(=O)c1cc(N2CCN(C(=O)OC(C)(C)C)CC2)cc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.49
MAPT P10636 3/20 0.47
NOTUM Q6P988 1/20 0.47
LMNA P02545 2/20 0.46
ALDH1A1 P00352 2/20 0.46
PDK2 Q15119 1/20 0.45
PHGDH O43175 1/20 0.45
SMN1; SMN2 Q16637 3/20 0.44
MET P08581 1/20 0.44
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GPR119 Q8TDV5 2/20 0.43
CYP2C19 P33261 1/20 0.43
CNR1 P21554 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
NAMPT P43490 1/20 0.43
POLB P06746 1/20 0.42
NR1H2 P55055 1/20 0.42
ALK Q9UM73 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31490516 0.89 MAPT (0.52) MAPTLMNAALDH1A1PDK2SMN1; SMN2
SCHEMBL23456298 0.88 STS (0.48) STSMAPTLMNAALDH1A1PDK2
SCHEMBL23217017 0.88 STS (0.54) STSMAPTLMNAALDH1A1PDK2
SCHEMBL19404303 0.86 MAPT (0.47) MAPTLMNAALDH1A1PDK2SMN1; SMN2
SCHEMBL19386233 0.85 NOTUM (0.51) MAPTNOTUMLMNAPHGDHSMN1; SMN2
SCHEMBL23456158 0.84 SMN1; SMN2 (0.53) STSMAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL19404282 0.84 KMT2A (0.51) MAPTLMNAALDH1A1PDK2SMN1; SMN2
SCHEMBL4934652 0.83 LMNA (0.47) MAPTNOTUMLMNAALDH1A1PDK2
SCHEMBL31252244 0.83 PHGDH (0.49) STSMAPTLMNAALDH1A1PDK2
SCHEMBL23228913 0.83 GPR119 (0.51) STSMAPTLMNAALDH1A1PDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11542254-B2 Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors UNIVERSISITY OF UTAH RESEARCH FOUNDATION (US) 2023-01-03 US disclosed
US-20210171502-A1 METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS UNITED STATES GOVERNMENT 2021-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171502-A1 METHODS AND COMPOSITION OF 4-SUBSTITUTED BENZOYLPIPERAZINE-1-SUBSTITUTED CARBONYLS AS BETA-CATENIN/B-CELL LYMPHOMA 9 INHIBITORS BCL9, BCL9L, BCL3 STS 4037/4885MAPT 2998/4885NOTUM 3714/4885
US-11542254-B2 Methods and composition of 4-substituted benzoylpiperazine-1-substituted carbonyls as beta-catenin/B-cell lymphoma 9 inhibitors BCL9, BCL9L, BCL3 STS 3907/4885MAPT 3080/4885NOTUM 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.